Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis
NCT01631617Phase 2Recruiting
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Sep 2012
- Primary completion
- Jan 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cefalexin, trimethoprim + sulfamethoxazole, doxycycline, sodium hypochlorite in atopic dermatitis (AD), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Started Sep 2012; status: recruiting.
02
Drugs
cefalexintrimethoprim + sulfamethoxazoledoxycyclinesodium hypochlorite
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01631617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01631617.